Results 111 to 120 of about 3,015 (158)

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries. [PDF]

BMJ Open Gastroenterol
Mustafa A, Davlidova S, Abidi SH, Begimbetova D, Heimer R, Vermund SH, Ali S.   +6 more
europepmc   +1 more source

Computational repurposing of polyphenols for anti-Mpoxviral activity. [PDF]

In Silico Pharmacol
Astakala RV, Preet G, Haj Hasan A, Desai R, Alfurayh M, Ebel R, Jaspars M.   +6 more
europepmc   +1 more source

Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil. [PDF]

Rev Soc Bras Med Trop
Hyppolito EB, Ramos AN, Teixeira LP, Bezerra AM, Mendes LA, Silva TL, Lima JMC, Arruda ÉAG, Guerra EJ, Tavares MMS, Lima CEP, Esmeraldo TM, Pessoa FSRP, Pierre AMM, Pereira KB, Araújo Filho AH, Linhares LMC, Ferreira AF, Pires Neto RDJ.   +18 more
europepmc   +1 more source

HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation. [PDF]

Drug Metab Dispos
Work HM, Hackett JC, Lampe JN.
europepmc   +1 more source

Using Organs from Hepatitis C-Infected Donors: A Cautionary Experience. [PDF]

Transplant Direct
Shanahan E, Yoshida EM, Chartier-Plante S, Hussaini T.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Simeprevir/sofosbuvir

Reactions Weekly, 2016
  +9 more sources

Simeprevir: First Global Approval

Drugs, 2013
Simeprevir (Sovriad(TM)) is a new direct-acting antiviral drug and a second-generation small-molecule NS3/4A serine protease inhibitor developed by Janssen and Medivir for the oral treatment of adults with genotype 1 and/or genotype 4 chronic hepatitis C virus (HCV) infection (chronic hepatitis C).
Asha, Vaidya, Caroline M, Perry
openaire   +2 more sources

Simeprevir/sofosbuvir

Reactions Weekly, 2015
  +7 more sources